GLORIA™-AF is a global Registry Program run in different phases and designed to characterize the population of newly diagnosed patients with non-valvular atrial fibrillation at risk for stroke, and to study patterns, predictors and outcomes of different treatment regimens for stroke prevention.

Patient characteristics, clinical usage patterns and patient outcomes of anticoagulation therapy will be documented in up to 56 000 patients in 2200 sites and more than 50 countries throughout the world.